Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $170,399 | 47 | 94.5% |
| Unspecified | $6,069 | 2 | 3.4% |
| Travel and Lodging | $2,898 | 11 | 1.6% |
| Food and Beverage | $849.73 | 16 | 0.5% |
| Education | $6.10 | 1 | 0.0% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $136,142 | 6 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $33,031 | 29 | $0 (2024) |
| AstraZeneca UK Limited | $7,300 | 15 | $0 (2023) |
| Amgen Inc. | $1,047 | 7 | $0 (2019) |
| Actelion Pharmaceuticals US, Inc. | $895.24 | 3 | $0 (2017) |
| Gilead Sciences, Inc. | $745.17 | 8 | $0 (2018) |
| AstraZeneca AB | $660.92 | 5 | $0 (2018) |
| Regeneron Pharmaceuticals, Inc. | $400.14 | 4 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $16,200 | 13 | AstraZeneca Pharmaceuticals LP ($16,200) |
| 2023 | $4,531 | 8 | AstraZeneca UK Limited ($3,425) |
| 2022 | $4,925 | 10 | AstraZeneca Pharmaceuticals LP ($2,775) |
| 2021 | $16,086 | 11 | PFIZER INC. ($10,549) |
| 2020 | $5,974 | 8 | AstraZeneca Pharmaceuticals LP ($3,075) |
| 2019 | $1,047 | 7 | Amgen Inc. ($1,047) |
| 2018 | $7,475 | 15 | AstraZeneca Pharmaceuticals LP ($6,069) |
| 2017 | $123,984 | 5 | PFIZER INC. ($123,088) |
All Payment Transactions
77 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/15/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
| Category: Respiratory | ||||||
| 10/15/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| 10/15/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Consulting Fee | Cash or cash equivalent | $400.00 | General |
| Category: Respiratory | ||||||
| 09/12/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Consulting Fee | Cash or cash equivalent | $3,200.00 | General |
| Category: Respiratory | ||||||
| 09/12/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Consulting Fee | Cash or cash equivalent | $400.00 | General |
| Category: Respiratory | ||||||
| 06/18/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Consulting Fee | Cash or cash equivalent | $200.00 | General |
| Category: Respiratory | ||||||
| 04/18/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Consulting Fee | Cash or cash equivalent | $3,050.00 | General |
| Category: Respiratory | ||||||
| 04/18/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Consulting Fee | Cash or cash equivalent | $650.00 | General |
| Category: Respiratory | ||||||
| 04/18/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Consulting Fee | Cash or cash equivalent | $200.00 | General |
| Category: Respiratory | ||||||
| 03/14/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| Category: Respiratory | ||||||
| 01/05/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: Respiratory | ||||||
| 01/05/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: Respiratory | ||||||
| 01/05/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: Respiratory | ||||||
| 10/04/2023 | PFIZER INC. | VYNDAMAX (Drug) | Education | In-kind items and services | $6.10 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/21/2023 | AstraZeneca UK Limited | BREZTRI (Drug) | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| Category: Respiratory | ||||||
| 09/21/2023 | AstraZeneca UK Limited | BREZTRI (Drug) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: Respiratory | ||||||
| 09/14/2023 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Consulting Fee | Cash or cash equivalent | $175.00 | General |
| Category: Respiratory | ||||||
| 06/16/2023 | AstraZeneca UK Limited | BREZTRI (Drug) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: Respiratory | ||||||
| 05/05/2023 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Consulting Fee | Cash or cash equivalent | $175.00 | General |
| Category: Respiratory | ||||||
| 04/26/2023 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| Category: Respiratory | ||||||
| 02/16/2023 | AstraZeneca UK Limited | BREZTRI (Drug) | Consulting Fee | Cash or cash equivalent | $1,275.00 | General |
| Category: Respiratory | ||||||
| 12/08/2022 | AstraZeneca UK Limited | BREZTRI (Drug) | Consulting Fee | Cash or cash equivalent | $350.00 | General |
| Category: Respiratory | ||||||
| 12/08/2022 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Consulting Fee | Cash or cash equivalent | $175.00 | General |
| Category: Respiratory | ||||||
| 10/13/2022 | AstraZeneca UK Limited | BREZTRI (Drug) | Consulting Fee | Cash or cash equivalent | $400.00 | General |
| Category: Respiratory | ||||||
| 08/18/2022 | AstraZeneca UK Limited | BREZTRI (Drug) | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| Category: Respiratory | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Multicentre Randomized Double Blind Placebo Controlled Parallel Group Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma | AstraZeneca Pharmaceuticals LP | $6,069 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2020 | 2 | 35 | 39 | $11,550 | $2,912 |
All Medicare Procedures & Services
2 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2020 | 17 | 18 | $6,300 | $1,602 | 25.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 18 | 21 | $5,250 | $1,311 | 25.0% |
About Dr. Hyung Chun, MD
Dr. Hyung Chun, MD is a Cardiovascular Disease healthcare provider based in New Haven, Connecticut. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1699852541.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Hyung Chun, MD has received a total of $180,221 in payments from pharmaceutical and medical device companies, with $16,200 received in 2024. These payments were reported across 77 transactions from 8 companies. The most common payment nature is "Consulting Fee" ($170,399).
As a Medicare-enrolled provider, Chun has provided services to 35 Medicare beneficiaries, totaling 39 services with total Medicare billing of $2,912. Data is available for 1 year (2020–2020), covering 2 distinct procedure/service records.
Practice Information
- Specialty Cardiovascular Disease
- Location New Haven, CT
- Active Since 10/31/2006
- Last Updated 09/21/2018
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1699852541
Products in Payments
- TEZSPIRE (Biological) $18,575
- XELJANZ (Drug) $10,549
- BREZTRI (Drug) $6,600
- VYNDAMAX (Drug) $6.10
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in New Haven
Dr. Jeffrey Testani, M.d, M.D
Cardiovascular Disease — Payments: $625,767
Henry Ward, M.d, M.D
Cardiovascular Disease — Payments: $404,260
Dr. John Forrest, M.d, M.D
Cardiovascular Disease — Payments: $232,147
Dr. Alexandra Lansky, Md, MD
Cardiovascular Disease — Payments: $205,439
Lissa Sugeng, Md, Mph, MD, MPH
Cardiovascular Disease — Payments: $106,815
Eric Velazquez, M.d, M.D
Cardiovascular Disease — Payments: $103,971